AZD-8529 is a potent, highly selective and orally bioavailable positive allosteric modulator of mGluR2 , with an EC 50 of 285 nM, and shows no positive allosteric modulator responses at 20-25 M on the mGluR1 , 3, 4, 5, 6, 7, and 8 subtypes.In VitroAZD-8529 potentiates the effects of glutamate at mGluR2 with an EC 50 of 195 nM. AZD-8529 does not elicit antagonist responses on mGluRs at 25 μM. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoAZD-8529 (0.3-mg/kg, i.m.) reduces nicotine priming-induced and cue-induced reinstatement in squirrel monkeys . AZD-8529 (30 mg/kg; i.p.) decreases the increased extracellular dopamine induced by nicotine in accumbens shell of freely-moving rats . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Sprague-Dawley rats Dosage: 10 mg/kg, 30 mg/kg Administration: Intraperitoneal injection; 2 hours before nicotine injections Result: Decreased the increased extracellular dopamine induced by nicotine (0.4 mg/kg, s.c.) in accumbens shell of freely-moving rats.IC50& Target:mGluR2 285 nM (EC 50 ). Specification: 10mM in DMSO Molecular Formula: C24H24F3N5O3 Molecular Weight: 487.47
- UPC:
- 51143219
- Condition:
- New
- Availability:
- 8-12 weeks
- Weight:
- 1.06 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- A654701-1ml
- CAS:
- 1092453-15-0
- Product Size:
- 1ml
